Bank of New York Mellon Corp raised its stake in shares of Five Prime Therapeutics Inc. (NASDAQ:FPRX) by 13.5% during the second quarter, Holdings Channel reports. The firm owned 149,061 shares of the company’s stock after buying an additional 17,694 shares during the period. Bank of New York Mellon Corp owned about 0.57% of Five Prime Therapeutics worth $6,164,000 as of its most recent filing with the SEC.

Several other institutional investors have also bought and sold shares of FPRX. Legal & General Group Plc raised its stake in Five Prime Therapeutics by 15.8% in the first quarter. Legal & General Group Plc now owns 3,869 shares of the company’s stock worth $160,000 after buying an additional 527 shares in the last quarter. Williams Jones & Associates LLC bought a new stake in Five Prime Therapeutics during the first quarter worth about $240,000. Meeder Asset Management Inc. bought a new stake in Five Prime Therapeutics during the second quarter worth about $268,000. Schonfeld Strategic Advisors LLC bought a new stake in Five Prime Therapeutics during the first quarter worth about $411,000. Finally, Gargoyle Investment Advisor L.L.C. bought a new stake in Five Prime Therapeutics during the second quarter worth about $426,000. Institutional investors own 86.49% of the company’s stock.

Shares of Five Prime Therapeutics Inc. (NASDAQ:FPRX) traded up 1.56% on Wednesday, hitting $52.82. 360,005 shares of the stock traded hands. The firm’s 50 day moving average is $47.48 and its 200 day moving average is $43.86. The firm has a market capitalization of $1.42 billion, a PE ratio of 5.94 and a beta of 4.51. Five Prime Therapeutics Inc. has a 52 week low of $14.70 and a 52 week high of $55.00.

Five Prime Therapeutics (NASDAQ:FPRX) last released its quarterly earnings data on Thursday, August 4th. The company reported ($0.49) earnings per share for the quarter, topping the consensus estimate of ($0.56) by $0.07. Five Prime Therapeutics had a net margin of 63.88% and a return on equity of 69.59%. The business had revenue of $9.23 million for the quarter, compared to analyst estimates of $6.38 million. During the same quarter last year, the firm earned ($0.45) EPS. Five Prime Therapeutics’s quarterly revenue was up 46.1% compared to the same quarter last year. On average, analysts expect that Five Prime Therapeutics Inc. will post ($2.37) EPS for the current fiscal year.

A number of analysts have recently issued reports on FPRX shares. Leerink Swann reissued an “outperform” rating and issued a $58.00 price target (up from $45.00) on shares of Five Prime Therapeutics in a research report on Monday, August 8th. Credit Suisse Group AG reissued a “buy” rating on shares of Five Prime Therapeutics in a research report on Wednesday, June 8th. Finally, Jefferies Group set a $60.00 price target on shares of Five Prime Therapeutics and gave the stock a “buy” rating in a research report on Friday, August 5th. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus price target of $52.33.

In related news, Director Peder Jensen sold 12,195 shares of Five Prime Therapeutics stock in a transaction that occurred on Wednesday, July 27th. The shares were sold at an average price of $49.50, for a total transaction of $603,652.50. Following the transaction, the director now owns 12,195 shares of the company’s stock, valued at approximately $603,652.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director William R. Ringo sold 500 shares of Five Prime Therapeutics stock in a transaction that occurred on Monday, August 1st. The stock was sold at an average price of $50.77, for a total transaction of $25,385.00. Following the transaction, the director now directly owns 500 shares in the company, valued at approximately $25,385. The disclosure for this sale can be found here. Corporate insiders own 5.30% of the company’s stock.

Five Prime Therapeutics Company Profile

Five Prime Therapeutics, Inc (Five Prime) is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company has three product candidates in clinical development covering multiple potential indications. It focuses on immuno-oncology, an area in which it has clinical and discovery programs, and product and discovery collaborations.

5 Day Chart for NASDAQ:FPRX

Want to see what other hedge funds are holding FPRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Five Prime Therapeutics Inc. (NASDAQ:FPRX).

Receive News & Ratings for Five Prime Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.